The field of drug discovery and development has experienced rapid evolution, with numerous new drugs receiving approval each year. While several books have been published on this subject, there is a pressing need for a new book series that accurately reflects the current advancements in drug discovery. This book aims to not only cater to the drug discovery community but also engage other communities involved in chemical biology, synthetic chemistry, and pharmacology. By showcasing how their work is utilized or has the potential to be utilized in the realm of drug discovery, this series intends to foster interdisciplinary collaboration and knowledge exchange. Considering the dynamic nature of drug discovery and development, where progress is swift and continuous, the authors have planned to release updated editions of the book every few years, ensuring that the content remains up to date with the latest achievements and breakthroughs in the field. Drug Discovery Stories, Volume 2 presents drug discovery stories of blockbuster drugs recently approved (2023-2024) and other promising drug candidates, including the structural biology and biological functions of the targets of interest, the identification of hit compounds, hit-to-lead optimization, binding mode of the key compounds with the target of interest (practically those guiding the drug design), key biological and PK data of lead compounds, clinical results if any, other candidate compounds in preclinical and clinical stage against the same target, and other contents that the authors want to include based on their choices.

• Analyzes the drug discovery stories of different blockbuster drugs
• Covers key aspects related to the drug development of the drugs
• Includes the newly approved drugs